• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Infection and Immunity >Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.
【2h】

Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.

机译：巴西儿童对脑膜炎奈瑟菌B群血清外膜蛋白疫苗的免疫应答：疗效比较。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Since 1986, serogroup B Neisseria meningitidis has caused approximately 80% of the meningococcal disease in Brazil. In 1988, an epidemic caused by N. meningitidis B:4:P1.15 was recognized in the greater São Paulo area of Brazil. The São Paulo state government decided to vaccinate children from 3 to 83 months of age with a vaccine consisting of serotype 4 outer membrane protein and group C meningococcal polysaccharide that was produced in Cuba. About 2.7 million children were vaccinated during two immunization campaigns conducted in 1989 and 1990. Because of this, a case-control study was designed to determine vaccine efficacy against group B meningococcal disease. The purpose of our study was to compare the antibody response with the protection from disease estimated from the case-control study. We measured the immune responses of vaccinees by enzyme-linked immunosorbent assay (ELISA), immunoblot, and bactericidal assay. The development of bactericidal antibodies was age dependent and in good agreement with the results of the case-control study. Only 40% of vaccinees showed fourfold or greater increases in bactericidal antibody titers after vaccination. A poor correlation between antibody levels detected by ELISA and those by bactericidal assay was found. Immunoblot analysis showed that about 50% of the serum samples with bactericidal titers higher than 1:4 were reactive with class 1 outer membrane protein. We conclude that the bactericidal assay is a good, laboratory-based, functional assay for the study of vaccine immunogenicity and that an effective solution to group B meningococcal disease remains to be demonstrated.
机译：自1986年以来，血清B型脑膜炎奈瑟氏球菌已引起巴西约80％的脑膜炎球菌病。 1988年，在巴西大圣保罗地区发现了由脑膜炎双球菌B：4：P1.15引起的流行病。圣保罗州政府决定为3至83个月大的儿童接种由古巴生产的4型血清外膜蛋白和C组脑膜炎球菌多糖疫苗。在1989年和1990年进行的两次免疫运动中，大约有270万儿童接种了疫苗。因此，进行了一项病例对照研究，以确定针对B组脑膜炎球菌疾病的疫苗效力。我们研究的目的是比较抗体反应与病例对照研究估计的对疾病的防护。我们通过酶联免疫吸附试验（ELISA），免疫印迹和杀菌试验测量了疫苗接种者的免疫反应。杀菌抗体的产生与年龄有关，并且与病例对照研究的结果非常吻合。疫苗接种后，只有40％的疫苗接种者的杀菌抗体效价提高了四倍或更多。发现通过ELISA检测的抗体水平与通过杀菌测定的抗体水平之间的相关性较弱。免疫印迹分析表明，杀菌滴度高于1：4的血清样品中约有50％与1类外膜蛋白发生反应。我们得出结论，杀菌试验是一种用于研究疫苗免疫原性的良好的，基于实验室的功能性试验，对B组脑膜炎球菌疾病的有效解决方案仍有待证明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号